Lipoic Acid for Progressive Multiple Sclerosis (MS) (LAPMS)

  • End date
    Aug 31, 2023
  • participants needed
  • sponsor
    VA Office of Research and Development
Updated on 5 March 2022
chronic progressive multiple sclerosis


The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.


This two-year study will determine if daily oral intake of lipoic acid will prove superior to placebo in reducing injury to the brain and maintaining mobility in progressive MS. Mobility will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as fall counts. Neuroprotection will be measured by the extent of brain volume loss seen on MRI.

Condition Multiple Sclerosis
Treatment Placebo, Lipoic acid
Clinical Study IdentifierNCT03161028
SponsorVA Office of Research and Development
Last Modified on5 March 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of progressive MS as defined by the study
Able to give informed consent and to adhere to study procedures
Expanded Disability Status Scale (EDSS) 3.0 - 6.5: ambulatory for at least 20 meters without rest and use of bilateral aids (canes, crutches, walker) or better

Exclusion Criteria

A self-reported medical or neurological problem other than MS that is a cause of progressive or fluctuating gait dysfunction
Unable to undergo MRI
Unable to follow directions in English as standardized scales are not all validated in other languages
Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures. Note: Stable abnormal laboratory values of no more than Grade 1 determined to not be of clinical significance to the primary treating physician for that condition may be permitted per local site investigator discretion
Pregnant or breast-feeding
Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications
Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment
IV or oral steroids in the 60 days prior to enrolment
Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months
Participation in the pilot LA in SPMS trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note